An 8-week, Dose Ranging, Open Label, Randomized, Phase 2 Study With a 44-week Extension, to Evaluate the Safety and Efficacy of MBX-8025 in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or Intolerance to Ursodeoxycholic Acid (UDCA)

Trial Profile

An 8-week, Dose Ranging, Open Label, Randomized, Phase 2 Study With a 44-week Extension, to Evaluate the Safety and Efficacy of MBX-8025 in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or Intolerance to Ursodeoxycholic Acid (UDCA)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Seladelpar (Primary)
  • Indications Primary biliary cirrhosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CymaBay Therapeutics
  • Most Recent Events

    • 31 Oct 2017 According to a CymaBay Therapeutics media release, interim results from the study were presented as an oral, late-breaking presentation at the Liver Meeting 2017.
    • 24 Oct 2017 Results analysing the correlation between the pruritus visual analogue scale (VAS) and 5-D itch scale in primary biliary cholangitis (PBC) patients from NCT02609048 and NCT02955602 studies, presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 09 Oct 2017 According to a CymaBay Therapeutics media release, interim data will be presented at The Liver Meeting hosted by the American Association for the Study of Liver Diseases (AASLD) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top